Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Royal Biologics is a life science company specializing in the development and commercialization of advanced regenerative cellular therapies and ortho-biologic solutions. The company provides a comprehensive portfolio of autologous and allogeneic tools designed for use in orthopedics, spinal surgery, and wound care. Its flagship product, Wound-X, is a tri-layer amniotic membrane used to facilitate healing in chronic and complex wounds by providing a natural scaffold for tissue regeneration. Royal Biologics focuses on delivering high-quality, evidence-based biologic solutions to improve patient outcomes and recovery times across various surgical and clinical applications. The company is headquartered in Hackensack, New Jersey, and serves a wide range of clinicians in the surgical and wound care markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Royal Wound X.